Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10137828 | 0.87 | CA1 (0.38) | CA1CYP2D6HDAC3HDAC1HDAC2 | |
| SCHEMBL29707466 | 0.85 | EPHX2 (0.39) | CA1CYP2D6HDAC3HDAC1HDAC2 | |
| SCHEMBL28632400 | 0.84 | CYP2D6 (0.42) | CA1CYP2D6HDAC3HDAC1HDAC2 | |
| SCHEMBL28634513 | 0.84 | CYP2D6 (0.42) | CA1CYP2D6HDAC3HDAC1HDAC2 | |
| SCHEMBL9112224 | 0.84 | CYP2D6 (0.39) | CA1CYP2D6HDAC3HDAC1HDAC2 | |
| SCHEMBL27475233 | 0.84 | CYP2D6 (0.42) | CA1CYP2D6HDAC3HDAC1HDAC2 | |
| SCHEMBL16077490 | 0.84 | HDAC1 (0.40) | CA1CYP2D6HDAC3HDAC1HDAC2 | |
| SCHEMBL22098470 | 0.84 | EPHX2 (0.41) | CA1CYP2D6HDAC3HDAC1HDAC2 | |
| SCHEMBL28243607 | 0.84 | EPHX2 (0.41) | CA1CYP2D6HDAC3HDAC1HDAC2 | |
| SCHEMBL31466178 | 0.84 | CYP2D6 (0.39) | CA1CYP2D6HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110981873-B | Preparation method for synthesizing pyrroloquinoline quinone by five-step method | 江西农业大学 | 2025-01-24 | — | — | CN | claimed |
| CN-109641904-A | The sulphur imido acyl group purine ketone compound that 7- for treating and preventing virus infection replaces | 豪夫迈·罗氏有限公司 | 2019-04-16 | — | — | CN | claimed |
| CN-101384601-A | Novel 6-amino-morphinan derivatives, method of manufacturing them and their application as analgesics | ALCASYNN PHARMACEUTICALS GMBH (AT) | 2009-03-11 | — | — | CN | claimed |
| CN-119977892-A | Preparation method and application of benzimidazole skeleton-containing compound | 中国科学院上海药物研究所 | 2025-05-13 | — | — | CN | disclosed |
| CN-110981873-B | Preparation method for synthesizing pyrroloquinoline quinone by five-step method | 江西农业大学 | 2025-01-24 | — | — | CN | disclosed |
| US-20240216513-A1 | FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-20230399317-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2023-12-14 | — | — | US | disclosed |
| US-20230399317-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2023-12-14 | — | — | US | disclosed |
| US-20230340018-A1 | MPRO CYSTEINE PROTEASE INHIBITORS | ANIXA BIOSCIENCES, INC. | 2023-10-26 | — | — | US | disclosed |
| CN-111801100-B | 7-substituted sulfoimidoyl purinone compounds and derivatives for the treatment and prevention of liver cancer | 豪夫迈·罗氏有限公司 | 2023-10-24 | — | — | CN | disclosed |
| US-20230321052-A1 | ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF | XOMA (US) LLC | 2023-10-12 | — | — | US | disclosed |
| CN-1114402-C | Isothiazolones | WARNER LAMBERT CO (US) | 2003-07-16 | — | — | CN | disclosed |
| CN-1100785-C | 1,3,4, 5-tetrahydrobenzo [ C ] azepine * -3-one disulfide derivatives and methods | MERVELL DOW PHARMACEUTICALS IN (US) | 2003-02-05 | — | — | CN | disclosed |
| CN-1066150-C | Bridged indoles as matrix metalloprotease inhibitors | SYNTEX INC (US) | 2001-05-23 | — | — | CN | disclosed |
| CN-1185737-A | Isothiazolones | WARNER LAMBERT CO (US) | 1998-06-24 | — | — | CN | disclosed |
| CN-1180358-A | Bridged indoles as matrix metalloprotease inhibitors | SYNTEX INC (US) | 1998-04-29 | — | — | CN | disclosed |
| CN-1140454-A | Novel mercaptoacetylamido-1,3,4,5-tetrahydro-benzo[c] azepin-3-one disulfide derivs. useful as inhibitors of enkephalinase and ACE | MERRELL DOW PHARMA (US) | 1997-01-15 | — | — | CN | disclosed |
| CN-1014515-B | Process for preparing nonaromatic fluoroallylamine as MAO inhibitor | MERRELL DOW PHARMA (US) | 1991-10-30 | — | — | CN | disclosed |
| CN-86108051-A | NONAROMATIC FLUOROALLYLAMINE MAO INHIBITORS | — | 1987-08-19 | — | — | CN | disclosed |
| EP-0224924-A2 | Non-aromatic fluorallylamine MAO inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1987-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399317-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | MPO, MUC1, CRYAB | CA1 609/4885CYP2D6 3265/4885HDAC3 1468/4885 |
| US-20240216513-A1 | FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE | FASN, FABP1, SCD | CA1 4318/4885CYP2D6 1066/4885HDAC3 1464/4885 |
| US-20230321052-A1 | ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF | PGF, PTGER1, PTGER4 | CA1 2136/4885CYP2D6 1425/4885HDAC3 2346/4885 |
| US-20230340018-A1 | MPRO CYSTEINE PROTEASE INHIBITORS | SERPINB1, PREP, PRCP | CA1 3745/4885CYP2D6 2476/4885HDAC3 1965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.